Copenhagen, November 6, 2006 Santaris Pharma, the Danish biopharmaceutical company developing RNA Antagonist drugs for the treatment of cancer and metabolic disorders, announced today that Keith McCullagh, President and Chief Executive Officer, will be presenting an overview of the company and progress in its product pipeline at the Rodman & Renshaw 8th Annual Healthcare Conference in New York, today, Monday November 6th at 15.55 pm, US Eastern Standard Time (21.20 Central European Time). The conference is being held at the New York Palace Hotel, New York City from November 6th-8th, 2006. A live webcast of the Santaris presentation may be accessed from the Investor Relations section of the company’s website, www.santaris.com, where it will also be archived and available after the presentation
About Santaris Pharma:
Santaris Pharma A/S is a clinical-stage biopharmaceutical company, engaged in researching and developing world leading drug candidates for inactivating the functions of specific disease associated RNAs. These innovative new drug products are based on the Company’s proprietary LNA® (Locked Nucleic Acid) technology for the treatment of cancer, metabolic disorders and other serious diseases. The Company was created in May 2003 and recently completed a €40 million new investment round from an international syndicate of premier life science venture investors. The Company’s drug pipeline is comprised of novel RNA Antagonist drugs based on its unique LNA® chemistry. LNA® drugs, with their high potency and biostability, have the potential to transform the field of RNA inhibiting therapeutics, making specific and effective gene silencing a reality in human medicine. If this potential is realised, even in part, it may be possible to design new drugs to treat a wide variety of human diseases by switching off the expression of harmful genes. Santaris Pharma holds the world wide patent rights to the exploitation of LNA® in pharmaceuticals and presently has three drugs in preclinical or clinical development. The lead drug candidate, SPC2996, is currently undergoing an international, multicentre, phase I/II clinical study in Chronic Lymphocytic Leukemia (CLL).
Further Information
For further information see www.santaris.com or contact:
Keith McCullagh, President & CEO
Tel. +45 4517 9819
km@santaris.com